Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.31)
# 387
Out of 4,960 analysts
226
Total ratings
46.01%
Success rate
19.04%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $4.61 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $25.74 | +8.78% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $123.11 | +21.84% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $118.51 | +29.10% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $13.08 | +7.03% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $43.96 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $15.61 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $19.56 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $37.86 | +53.20% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $29.75 | +44.54% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $38.34 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.77 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $135.43 | +14.45% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.41 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $15.49 | +125.95% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.75 | +173.68% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.15 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.81 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.19 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.57 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $21.08 | +61.29% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $30.92 | +61.71% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.93 | -15.68% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.35 | +1,059.42% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.10 | +263.64% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $38.84 | +49.33% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,100 | $1.60 | +68,650.00% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $5.66 | +1,313.43% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.17 | +156.41% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $9.53 | +15.42% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $8.66 | +38.57% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $7.84 | +2,042.86% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.14 | +834.58% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $16.00 | +1,150.00% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.03 | +288.35% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.20 | +990.91% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.96 | +7,246.94% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.46 | +173.97% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $71.82 | -45.70% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $70.33 | -78.67% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.59 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $3.54 | +4,984.75% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.61
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $25.74
Upside: +8.78%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $123.11
Upside: +21.84%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $118.51
Upside: +29.10%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $13.08
Upside: +7.03%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $43.96
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.61
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.56
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $37.86
Upside: +53.20%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $29.75
Upside: +44.54%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $38.34
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.77
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $135.43
Upside: +14.45%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.41
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $15.49
Upside: +125.95%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.75
Upside: +173.68%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.15
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.81
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.19
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.57
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $21.08
Upside: +61.29%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $30.92
Upside: +61.71%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.93
Upside: -15.68%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.35
Upside: +1,059.42%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.10
Upside: +263.64%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $38.84
Upside: +49.33%
Aug 22, 2023
Reiterates: Overweight
Price Target: $1,100
Current: $1.60
Upside: +68,650.00%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $5.66
Upside: +1,313.43%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.17
Upside: +156.41%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $9.53
Upside: +15.42%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.66
Upside: +38.57%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $7.84
Upside: +2,042.86%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.14
Upside: +834.58%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $16.00
Upside: +1,150.00%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.03
Upside: +288.35%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.20
Upside: +990.91%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.96
Upside: +7,246.94%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.46
Upside: +173.97%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $71.82
Upside: -45.70%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $70.33
Upside: -78.67%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.59
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $3.54
Upside: +4,984.75%